CA2015687A1 - Human serum albomin fusion polypeptide - Google Patents

Human serum albomin fusion polypeptide

Info

Publication number
CA2015687A1
CA2015687A1 CA2015687A CA2015687A CA2015687A1 CA 2015687 A1 CA2015687 A1 CA 2015687A1 CA 2015687 A CA2015687 A CA 2015687A CA 2015687 A CA2015687 A CA 2015687A CA 2015687 A1 CA2015687 A1 CA 2015687A1
Authority
CA
Canada
Prior art keywords
terminal
terminal portion
human serum
fusion polypeptide
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2015687A
Other languages
French (fr)
Other versions
CA2015687C (en
Inventor
David J. Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albumedix Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2015687A1 publication Critical patent/CA2015687A1/en
Application granted granted Critical
Publication of CA2015687C publication Critical patent/CA2015687C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of human serum albumin (HSA) or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is one of various specified entities, including the 585 to 1578 portion of human fibronectin or a variant thereof. The HSA-like portion may have additional N-terminal residues, such as secretion leader sequences (signal sequences). The C-terminal portion is preferably the 585-1578 portion of human plasma fibronectin.
The N-terminal and C-terminal portions may be cleavable to yield the isolated C-terminal portion, with the N-terminal portion having served to facilitate secretion from the host.
CA002015687A 1989-04-29 1990-04-27 Human serum albomin fusion polypeptide Expired - Lifetime CA2015687C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898909916A GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides
GBGB8909916.2 1989-04-29

Publications (2)

Publication Number Publication Date
CA2015687A1 true CA2015687A1 (en) 1990-10-29
CA2015687C CA2015687C (en) 2000-08-29

Family

ID=10656000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002015687A Expired - Lifetime CA2015687C (en) 1989-04-29 1990-04-27 Human serum albomin fusion polypeptide

Country Status (12)

Country Link
EP (1) EP0470165A1 (en)
JP (1) JP2781459B2 (en)
KR (1) KR100227167B1 (en)
AU (1) AU630450B2 (en)
CA (1) CA2015687C (en)
FI (1) FI104255B (en)
GB (2) GB8909916D0 (en)
HU (1) HUT61049A (en)
IE (1) IE67651B1 (en)
IL (1) IL94243A (en)
WO (1) WO1990013653A1 (en)
ZA (1) ZA903237B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686900B1 (en) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
GB9408466D0 (en) * 1994-04-27 1994-06-22 Univ Nottingham Cloning and functional expression of neurotoxins
US5543308A (en) * 1994-10-18 1996-08-06 New England Biolabs, Inc. Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
MY120425A (en) * 1996-07-26 2005-10-31 Novartis Ag Fusion polypeptides
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
US5932693A (en) * 1996-12-10 1999-08-03 Washington University Antithrombotic peptides
KR20010034305A (en) 1998-01-23 2001-04-25 한센 핀 베네드 Process for making desired polypeptides in yeast
DE69933216T2 (en) 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham ERYTHROPOIETIN ANALOG HUMAN SERUM ALBUMIN FUSION PROTEIN
WO2001079480A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003016511A1 (en) 2001-08-15 2003-02-27 Takara Bio Inc. Method of extended culture for antigen-specific cytotoxic t lumphocytes
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
ATE491021T1 (en) 2002-03-25 2010-12-15 Takara Bio Inc METHOD FOR PRODUCING A CYTOTOXIC LYMPHOCYTE
WO2005019450A1 (en) * 2003-08-22 2005-03-03 Takara Bio Inc. Process for producing cytotoxic lymphocytes
EP3192872A1 (en) 2003-08-26 2017-07-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2007274035A1 (en) 2006-07-13 2008-01-17 Novozymes Biopharma Dk A/S Process for preparing particles of proteinaceous material
DK2396347T3 (en) 2009-02-11 2017-07-24 Albumedix As ALBUMIN VARIANTS AND CONJUGATES
CN105567699A (en) 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 Albumin variants
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
KR20200044138A (en) 2011-06-24 2020-04-28 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
BR112014018679A2 (en) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As albumin variants
RU2670063C2 (en) 2012-11-08 2018-10-17 Альбумедикс А/С Albumin variants
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
AU2016308504A1 (en) 2015-08-20 2018-01-18 Albumedix Ltd. Albumin variants and conjugates
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE459586B (en) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides

Also Published As

Publication number Publication date
FI915073A0 (en) 1991-10-28
GB2246783B (en) 1992-10-14
IE67651B1 (en) 1996-04-17
FI104255B1 (en) 1999-12-15
GB2246783A (en) 1992-02-12
GB8909916D0 (en) 1989-06-14
AU5564690A (en) 1990-11-29
AU630450B2 (en) 1992-10-29
FI104255B (en) 1999-12-15
KR920701451A (en) 1992-08-11
EP0470165A1 (en) 1992-02-12
HUT61049A (en) 1992-11-30
JP2781459B2 (en) 1998-07-30
ZA903237B (en) 1991-03-27
HU904413D0 (en) 1992-01-28
IL94243A (en) 1995-10-31
KR100227167B1 (en) 1999-10-15
IL94243A0 (en) 1991-01-31
WO1990013653A1 (en) 1990-11-15
IE901554L (en) 1990-10-29
CA2015687C (en) 2000-08-29
JPH04506598A (en) 1992-11-19
GB9119043D0 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
CA2015687A1 (en) Human serum albomin fusion polypeptide
CA2050336A1 (en) Yeast processing system comprising a negatively charged amino acid adjacent to the processing site
AU9156291A (en) Polypeptide analogs of apolipoprotein e, diagnostic systems and methods using the analogs
AU543198B2 (en) Hexapeptides
EP0370989A3 (en) Human vascular permeability factor
IL70601A (en) Synthetic heat-stable enterotoxin polypeptides of escherichia coli,multimers thereof,vaccines,diagnostic systems and network polymers including same and methods for their preparation
EP0330451A3 (en) A cdna coding for human normal serum albumin a, and a process for production of the albumin
AU4647889A (en) Insect signal peptide mediated secretion of recombinant proteins
AU6332399A (en) Member of the tnf ligand family
AU3498189A (en) Fibronectin binding protein
ZA905480B (en) Antagonists of gm-csf derived from the carboxyl terminus
KR100295606B1 (en)
EP0187721A3 (en) Preparation of peptide substrates for virus-specified proteases
WO2001025438A3 (en) Ifn-alpha homologues
EP0249477A3 (en) Functional recombinant analog polypeptides devoid of hydrophobic amino acids
CA2083177A1 (en) Alveolar surfactant proteins
Gluschankof et al. The somatostatin-28 convertase of rat brain cortex generates both somatostatin-14 and somatostatin-28 (1–12)
CA2133834A1 (en) Process for preparing modified proteins
WO1988006625A3 (en) Arginine-depleted human tumor necrosis factor
AU8680691A (en) Intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
AU7166891A (en) Method of purifying recombinant polypeptides
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
AU2117388A (en) Recombinant htlv-iii proteins and uses thereof
AU4076189A (en) Recombinant fusion proteins for altering hormone secretion
AU637589B2 (en) Ancrod proteins, their production and use

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry